Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma

Next Previous
X
Search
Trial Profile

Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Irinotecan (Primary) ; Pazopanib (Primary) ; Temozolomide (Primary)
  • Indications Ewing's sarcoma; Osteosarcoma; Primitive neuroectodermal tumours; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions
  • Acronyms PAZIT

    • Most Recent Events

    • 30 Dec 2020 Status changed from active, no longer recruiting to completed.
    • 31 May 2020 The protocol was amended to the dose escalation plan and patients received fixed doses of pazopanib PO (225 mg/m2/dose) and reduced irinotecan doses (IV 25-37.5 or PO 45-67.5 mg/m2/dose) and temozolomide PO 100 mg/m2/dose on Days 1-5, as per the results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top